RGH-896 IN PATIENTS WITH NEUROPATHIC PAIN DUE TO SPINAL CORD INJURY

RGH-896 用于脊髓损伤引起的神经病理性疼痛患者

• 批准号: 7379256
• 负责人: CHRISTINE NAI-MEI SANG
• 金额: $ 5.44万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379256
• 关键词: RGH; 896; PATIENTS; NEUROPATHIC; PAIN

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to assess the efficiency of a well-tolerated oral dose of RGH-896 compared with that of placebo administered for 4 weeks in reducing neuropathic pain associated with spinal cord injury. This is an investigator initiated, industry funded study.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项研究的目的是评估口服良好的RGH-896口服剂量的效率，而在减少与脊髓损伤相关的神经性疼痛中施用了4周的安慰剂。这是研究人员发起的行业资助研究。